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Abstract
Tetrahydrobiopterin (BH4) is a co-factor required for catalytic activity of nitric oxide synthase
(NOS) and amino acid-monooxygenases, including phenylalanine hydroxylase. BH4 is un-
stable: during oxidative stress it is non-enzymatically oxidized to dihydrobiopterin (BH2),
which inhibits NOS. Depending on BH4 availability, NOS oscillates between NO synthase
and NADPH oxidase: as the BH4/BH2 ratio decreases, NO production falls and is replaced
by superoxide. In African children and Asian adults with severe malaria, NO bioavailability
decreases and plasma phenylalanine increases, together suggesting possible BH4 defi-
ciency. The primary three biopterin metabolites (BH4, BH2 and B0 [biopterin]) and their asso-
ciation with disease severity have not been assessed in falciparum malaria. We measured
pterin metabolites in urine of adults with severe falciparum malaria (SM; n=12), moderately-
severe malaria (MSM, n=17), severe sepsis (SS; n=5) and healthy subjects (HC; n=20) as
controls. In SM, urinary BH4 was decreased (median 0.16¼mol/mmol creatinine) compared
to MSM (median 0.27), SS (median 0.54), and HC (median 0.34)]; p<0.001. Conversely,
BH2 was increased in SM (median 0.91¼mol/mmol creatinine), compared to MSM (median
0.67), SS (median 0.39), and HC (median 0.52); p<0.001, suggesting increased oxidative
stress and insufficient recycling of BH2 back to BH4 in severe malaria. Overall, the median
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BH4/BH2 ratio was lowest in SM [0.18 (IQR: 0.04-0.32)] compared to MSM (0.45, IQR 0.27-
61), SS (1.03; IQR 0.54-2.38) and controls (0.66; IQR 0.43-1.07); p<0.001. In malaria, a
lower BH4/BH2 ratio correlated with decreased microvascular reactivity (r=0.41; p=0.03)
and increased ICAM-1 (r=-0.52; p=0.005). Decreased BH4 and increased BH2 in severe
malaria (but not in severe sepsis) uncouples NOS, leading to impaired NO bioavailability
and potentially increased oxidative stress. Adjunctive therapy to regenerate BH4 may have
a role in improving NO bioavailability and microvascular perfusion in severe
falciparum malaria.
Author Summary
Vascular nitric oxide (NO) bioavailability is decreased in severe falciparummalaria and as-
sociated with microvascular dysfunction and increased endothelial activation. Nitric oxide
synthase (NOS) requires tetrahydrobiopterin (BH4) as a co-factor to convert L-arginine to
NO, but when BH4 is low, NOS is “uncoupled” and produces superoxide instead of NO. In
conditions of increased oxidative stress, BH4 is converted to dihydrobiopterin (BH2) and
biopterin (B0): the resulting BH2 competes with remaining BH4 as a competitive inhibitor
of NOS, further decreasing NO production. We measured BH4 and BH2 in the urine of
adults with severe and uncomplicated falciparummalaria and compared results to those of
controls or those with sepsis. There was a significant decrease in urinary BH4 and increase
in BH2 in severe malaria compared to uncomplicated malaria, sepsis, and controls, suggest-
ing increased oxidative stress and insufficient recycling of BH2 back to BH4. The BH4/BH2
ratio was associated with increased risk of severe disease, endothelial activation and micro-
vascular dysfunction, likely through impaired NOS function. This additional mechanism of
decreased NO in severe malaria suggests that trials evaluating use of adjunctive L-arginine
to increase NO in severe malaria may require concurrent therapy to regenerate BH4.
Introduction
Malaria remains the most important parasitic infection in humans, causing an estimated 207
million cases and 627,000 deaths in 2010 [1,2]. Mortality from severe Plasmodium falciparum
malaria has decreased with use of intravenous artesunate, but case fatality rates remain at 8%
and 15% for African children and Asian adults [3,4]. Improved understanding of the pathogen-
esis of severe falciparum malaria may allow identification of new targets for adjunctive therapy.
Decreased nitric oxide (NO) bioavailability is associated with increased disease severity in
African children as well as Asian adults and children with falciparum malaria [5–7], but the
full reasons for this observation are not known. Mechanisms identified to date include low lev-
els of L-arginine [the substrate for NO synthase (NOS)] [6,8], impaired mononuclear cell
NOS2 expression [5], inhibition of NOS by ADMA [9,10], and quenching of NO by increased
plasma cell-free hemoglobin [11]. In Asian adults with moderately severe falciparum malaria
(MSM), L-arginine infusion increased endothelial NO and pulmonary NO bioavailability [6].
However, a pilot trial of low-dose L-arginine infusion in adult severe falciparum malaria (SM)
did not result in improvement in endothelial NO bioavailability or lactate clearance [12].
While greater L-arginine clearance in severe malaria suggest that higher doses may be more ef-
fective [12], additional mechanisms beyond L-arginine deficiency are likely to be involved.
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Tetrahydrobiopterin (BH4) is an obligate co-factor for NO synthesis by NOS [13,14]. BH4
stabilizes the homodimeric NOS enzyme and participates in L-arginine oxidation and heme-
iron reduction for NO production. NOS lacking BH4 remains catalytically active, transferring
electrons from NADPH to dioxygen to produce superoxide [14,15]. Conversion of NOS cataly-
sis from NO synthesis to superoxide production under conditions of low or absent BH4 is
termed “uncoupling,”meaning that NADPH consumption and oxygen activation are no longer
“coupled” to BH4-dependent L-arginine oxygenation [14,15]. In an oxidizing environment,
NOS uncoupling may be related to the instability of BH4 because this reduced pterin spontane-
ously oxidizes to quininoid-BH2, which rapidly rearranges to the stable metabolite 7,8-dihydro-
biopterin (BH2) that is inactive as a cofactor for NO synthesis. BH2 can be reduced back to BH4
via a tetrahydrofolate-dependent salvage pathway [16]. However if BH2 levels rise at the ex-
pense of BH4 oxidation, BH2 competes with BH4 at the NOS active site leading to NOS uncou-
pling and superoxide production. In cardiovascular disease, an increased BH4/BH2 ratio (as
opposed to the BH4 concentration alone) has been found to be the best correlate for endothelial
cell-dependent NO synthesis [14,15].
BH4 is also a co-factor for the enzyme phenylalanine hydroxylase that converts phenylala-
nine to tyrosine in the liver. We have found in both African children with cerebral malaria
(CM) and Asian adults with SM that plasma phenylalanine levels are markedly increased [17].
We hypothesized that in SM the systemic level of BH4, relative to the oxidized biopterin species
(BH2 + B0), would be decreased. This could explain depression in both phenylalanine hydroxy-
lase activity and NOS functionality in severe malaria. Biopterin oxidation states in plasma and
urine (which reflect systemic levels) have not been measured in malaria. Therefore we under-
took measurements of urinary BH4, BH2 and B0 in Indonesian adults with SM and MSM and
compared these to levels in healthy controls and a group presenting with severe sepsis. We hy-
pothesized that (a) BH4 levels and BH4/BH2 ratios would be decreased, and BH2 increased in
proportion to malaria disease severity, and (b) decreased BH4/BH2 ratios would be associated
with increased endothelial activation and impaired NO-dependent microvascular reactivity.
Results
Patients
The clinical features of these subjects have previously been described [18]. We measured uri-
nary pterin metabolites in their various oxidized states [(including biopterin (B0), 7, 8 dihydro-
biopterin (BH2), tetrahydrobiopterin (BH4), dihydroneopterin (NH2) and neopterin (N0)]
levels in 12 adults with severe malaria (SM) and 17 with moderately severe malaria (MSM),
with 20 healthy adults (HCs) and 5 with severe sepsis (SS) as controls. In SM patients, 5 had
single organ dysfunction (4 with cerebral malaria and 1 with acute renal failure), while the re-
maining 7 had two or more severity criteria. All SM and MSM patients received intravenous
artesunate. In SS patients, two had pneumonia and gastroenteritis, and one each had pneumo-
nia, gastroenteritis, and meningitis. There were 4 deaths in the SM group, and none in the
MSM and SS patients. The baseline demographic details, clinical features, hematological and
biochemical results of the patients are summarized in Table 1.
BH4, BH2, BH4/BH2 ratio, B0, NH2, N0 and clinical disease
BH4 was decreased in patients with SM (median 0.16 μmol/mmol creatinine; IQR 0.04–0.30)
compared to those with MSM (0.27, IQR 0.19–0.41), SS (0.54; IQR 0.48–0.94), and controls
(0.34; IQR 0.27–0.46); Kruskal-Wallis p<0.001 (Table 2, Fig. 1A). In contrast, BH2 was in-
creased in SM (median 0.91 μmol/mmol creatinine; IQR 0.62–1.35) compared to MSM (0.67;
IQR 0.52–0.76), SS (0.39; IQR 0.38–0.88) and HCs (0.52: IQR 0.43–0.69); Kruskal-Wallis
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p<0.001 (Table 2, Fig. 1B). The BH4/BH2 ratio was also decreased in patients with SM (median
0.17; IQR 0.04–0.32) compared to those with MSM (0.45, IQR 0.27–61), SS (1.03; IQR
0.54–2.38) and controls (0.66; IQR 0.43–1.07); Kruskal-Wallis p<0.001 (Table 2, Fig. 1C).
Conversely NH2 and N0 levels were increased in SM compared to MSM, SS, and HCs
(p<0.001) (Table 2), but there were no significant differences in the total biopterin
(BH4+BH2+B0) levels among groups (p = 0.1) (Table 2, Fig. 1D). The ratio of reduced:oxidized
neopterin (NH2:N0) was 4.4 in healthy controls compared to 2.0 in severe malaria (p = 0.002,
Table 2). In the 29 patients with malaria, an increased BH4/BH2 ratio was associated with se-
vere disease (p = 0.03), however no significant associations were found for BH4, BH2, B0, total
biopterin, NH2, N0 and total neopterin. The risk of death in malaria was not associated with
levels of any of the pterin metabolites. There was no association between serum creatinine and
urinary BH4, BH2, N0 and NH2 in patients with malaria and in the groups with severe or un-
complicated disease. On controlling for blood creatinine, there was still a significant difference
in urinary BH2 (p = 0.011) and BH4/BH2 (p = 0.04) levels but not BH4 between the groups.
BH4, BH2, BH4/BH2 ratio, and biomarkers of severity
Peripheral parasitemia was correlated with increasing BH2 (r = 0.46, p = 0.01) and N0 (r = 0.50,
p = 0.006) levels, and parasite biomass (estimated using plasma HRP2) was positively correlat-
ed with BH2 (r = 0.44, p = 0.02), and inversely with the BH4/BH2 ratio (r = -0.41, p = 0.03) in
all malaria patients but not after controlling for malarial disease severity. Increasing venous lac-
tate was associated with higher BH2 levels (r = 0.48, p = 0.008) and a lower BH4/BH2 ratio
(r = -0.43, p = 0.01) in all malaria patients but not after controlling for severity of disease.
Table 1. Baseline demographics, clinical and laboratory measurements.
Healthy
Controls
Moderately-severe
malaria
Severe Malaria Severe Sepsis
Number 20 17 12 5
Age; years, (median, IQR) 29 (21–35) 28 (23–32) 30 (21–37) 25 (24–26)
Males; (number, percentage) 18 (90%) 11 (65%) 9 (75%) 1 (20%)
Days of fever before presentation (median, IQR) NA 2 (2–5) 3 (2–5) 2 (2–5)
Systolic Blood Pressure; median (IQR), (mmHg)* 117 (113–126) 106 (100–115) 110 (101–132) 99 (94–101)
Diastolic Blood Pressure; median (IQR), (mmHg)* 70 (65–75) 59 (57–64) 64 (61–73) 64 (60–70)
Pulse Rate; median (IQR), (beats/min)* 65 (60–73) 80 (75–88) 90 (80–97) 104 (103–104)
Pulse Oxygen Saturation; mean (range), (% saturation) 99 (96–100) 98 (94–100) 96 (75–100) 99 (96–100)
Temperature; mean (range) (°Celsius)* 36.1 (35–37) 37.1 (35.9–38.9) 37.0 (35.8–39.6) 37.2 (36.7–
38.0)
Leukocyte count; median (IQR), x103/μL* 6.1 (4.5–6.8) 4.2 (3.7–5.8) 9.8 (7.4–12.0) 18.1 (15.4–
22.1)
Hemoglobin; mean (range), (g/dl)* 12.8 (11.2–15.5) 11.5 (9.4–13.3) 12.0 (11.2–13.9) 9.2 (8.8–11.9)
Platelet; median (IQR), x109/L * 153 (110–200) 53 (48–80) 26 (20–98) 96 (76–201)
Creatinine; median (IQR), (μmol/L)* (normal range: 50 to 110
μmol)
NA 87 (74–106) 182.5 (109–330) 80 (57–230)
Lactate; median ((IQR), (mmol/L)* (normal range: 0 to 2mmol) NA 1.08 (0.9–1.8) 3.11 (1.9–5.1) 1.31 (1.2–1.5)
Parasite Density; Geometric Mean (95%CI), (parasite/μL)* NA 14512 (8103–25989) 29269 (6453–
132740)
NA
Histidine Rich Protein 2; Median (IQR), (loge ng/ml) NA 2.76 (1.94–3.22) 4.26 (3.79–6.86) NA
*p<0.05 (for ANOVA, Kruskal-Wallis or χ2 test comparing severe malaria, moderately-severe malaria, severe sepsis and healthy controls)
doi:10.1371/journal.ppat.1004667.t001
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BH4, BH2, BH4/BH2 ratio, microvascular reactivity, and endothelial activation. Similar
to our previous published results [18], microvascular reactivity and endothelial function were
reduced in SM compared to MSM and HCs (Table 2). In all malaria patients, higher microvas-
cular reactivity was associated with an increased BH4/BH2 ratio (r = 0.41, p = 0.03) and lower
BH2 levels (r = -0.42, p = 0.024), with no association found for the other biopterin metabolites.
The associations with the BH4/BH2 ratio and BH2 remained significant after controlling for
disease severity (partial correlation coefficient = 0.34, p = 0.04 and partial correlation coeffi-
cient = -0.38, p = 0.04, respectively). Impaired endothelial function was also associated with in-
creasing BH2 in all malaria patients (r = -0.42, p = 0.03) and those with severe malaria (r =
-0.48, p = 0.04) but not in the MSM group alone. The association between endothelial function
and BH2 remained significant after controlling for disease severity (partial correlation coeffi-
cient = -0.37, p = 0.04). Evaluation of markers of endothelial activation showed that ICAM-1
levels were positively associated with BH2 (r = 0.4, p = 0.02) and inversely associated with BH4
(r = -0.38, p = 0.04) and the BH4/BH2 ratio (r = -0.52, p = 0.003) in all malaria patients, but
only with BH4/BH2 (r = -0.63, p = 0.03) in the SM group. The association between ICAM-1
with BH4 (partial correlation coefficient = -0.38, p = 0.035) and the BH4/BH2 ratio (partial
Table 2. Microvascular reactivity, endothelial function and biopterin metabolite values among patient groups.
Healthy
Controls
P
value†
Moderately-severe
malaria
P
value††
Severe
Sepsis
P
value†††
Severe
Malaria
Number 20 17 5 12
Recovery StO2%second* (StO2recov)
Median (IQR) *
3.5 (3.0–3.7) 0.04 3.2 (2.75–3.85) 0.1 3.1 (2.6–4.0) 0.05 2.8 (1.8–3.4)
Reactive Hyperemia Peripheral Arterial
Tonometry*
1.76 (1.45–
2.15)
0.06 1.77 (1.6–2.2) 0.04 1.56 (1.36–
1.68)
0.2 1.38 (1.27–
1.87)
Tetrahydrobiopterin (BH4) * 0.34 (0.27–
0.46)
0.006 0.27 (0.19–0.41) 0.08 0.54 (0.48–
0.94)
0.008 0.16 (0.04–
0.30)
7, 8 dihydrobiopterin (BH2) * 0.52 (0.43–
0.69)
0.002 0.67 (0.52–0.76) 0.03 0.39 (0.38–
0.88)
0.05 0.91 (0.62–
1.35)
B0 Biopterin* 0.01 (0–0.02) 0.02 0.02 (0.01–0.03) 0.08 0.03 (0.02–
0.07)
0.08 0.06 (0.01–
0.19)
Urine Total Biopterins (BH4 + BH2 + B0) 0.94 (0.75–
1.18)
0.09 0.94 (0.76–1.17) 0.2 1.42 (1.35–
1.45)
0.6 1.14 (0.89–
1.84)
BH4/BH2 ratio* 0.67 (0.43–
1.08)
0.001 0.45 (0.27–0.62) 0.01 1.03 (0.54–
2.38)
0.003 0.18 (0.04–
0.32)
Dihydroneopterin (NH2) * 1.73 (0.95–
3.20)
0.001 6.9 (4.90–8.00) 0.6 3.02 (2.57–
4.80)
0.1 6.2 (4.35–
9.78)
Neopterin (N0) * 0.45 (0.21–
0.72)
<0.0001 1.86 (1.29–2.84) 0.03 0.85 (0.77–
1.47)
0.02 4.16 (2.04–
5.11)
Total Neopterin (NH2 + N0) * 2.19 (1.16–
3.90)
<0.0001 8.65 (6.40–10.67) 0.2 3.87 (3.3–
6.24)
0.03 10.78 (6.55–
13.60)
NH2/N0 Ratio 4.44 (2.52–8) 0.002 3.57 (2.32–5.38) 0.03 3.23 (2.9–
3.58)
0.17 1.98 (0.54–
5.48)
Phenylalanine (μmol/L) * 54 (51–58) 0.03 101 (84–110) 0.09 114 (112–
332)
0.2 176 (85–250)
Median and IQR unless otherwise stated. All pterin measurements are μmol/mmol creatinine
*p<0.05 (for ANOVA, Kruskal-Wallis or χ2 test comparing severe malaria, moderately-severe malaria, severe sepsis and healthy controls)
†Pairwise comparisons between each group and severe malaria using Wilcoxon-Mann-Whitney test: † control vs severe malaria;
†† moderately severe malaria vs severe malaria;
††† severe sepsis vs severe malaria.
doi:10.1371/journal.ppat.1004667.t002
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Fig 1. Urinary BH4, BH2 concentrations, BH4/BH2 ratios and Biopterin concentration in each group
on enrollment (Kruskal-Wallis: p<0.001). Horizontal bars represent pairwise comparisons between
disease groups. A. Urine BH4 (μmol/mmol creatinine) concentrations in each group on enrollment.
Horizontal lines indicate median values for each group. B. Urine BH2 (μmol/mmol creatinine) concentrations
in each group on enrollment. Horizontal lines indicate median values for each group. C. BH4/BH2 ratio in
Decreased Tetrahydrobiopterin and Severity in Adult FalciparumMalaria
PLOS Pathogens | DOI:10.1371/journal.ppat.1004667 March 12, 2015 6 / 13
correlation coefficient = -0.40, p = 0.03) remained significant after adjustment for malaria se-
verity. The level of angiopoietin-2, another marker of malaria severity, was associated with in-
creasing BH2 (r = 0.44, p = 0.02), but was not significant after adjusting for disease severity.
Plasma phenylalanine, and BH4, BH2, and the BH4/BH2 ratio
Plasma phenylalanine levels were significantly increased in SM (median 176 μmol/L, IQR
85–250) compared to MSM (101μmol/L; IQR 84–110), SS (114μmol/L; IQR 112–332), and
HCs (54μmol/L; IQR 51–58); Kruskal-Wallis p<0.001 (Table 2). Among all patients with ma-
laria, plasma phenylalanine levels were inversely related to the BH4/BH2 ratio (r = -0.44, p =
0.04, including after controlling for disease severity [partial correlation coefficient = -0.38, p =
0.04]) and positively related to BH2 levels (r = 0.39, p = 0.03, including after controlling for dis-
ease severity [partial correlation coefficient = 0.48, p = 0.02]), but not BH4, B0, NH2, or N0.
Discussion
In adults with falciparum malaria, urinary tetrahydrobiopterin (BH4) was decreased and 7, 8-
dihydrobiopterin (BH2) increased in proportion to disease severity, and a decreased BH4/BH2
ratio was associated with an increased risk of severe disease. The BH4/BH2 ratio is a reliable
correlate for endothelial cell-dependent NO synthesis in vascular diseases [14–16]. The finding
of an association between decreased BH4/BH2 ratio and increased BH2 with impaired micro-
vascular reactivity and increased endothelial activation is consistent with a mechanistic role for
oxidative stress and vascular NOS dysfunction. The association of increased BH2 and low BH4/
BH2 ratios with increased phenylalanine levels suggests that systemic deficiency of BH4 causes
impaired phenylalanine hydroxylase function as well as NOS dysfunction in malaria.
We have previously shown decreased systemic NO production in both African children and
Indonesian adults, proportional to disease severity [5,6]. In adult falciparum malaria, there is
also decreased endothelial and pulmonary NO bioavailability associated with low levels of the
NOS substrate L-arginine [6], increased levels of the endogenous NOS inhibitor asymmetric
dimethylarginine (ADMA) [10], NO quenching by cell-free hemoglobin [11] and L-arginine
reversible endothelial dysfunction in moderately severe malaria [6]. The role of the key NOS
cofactor, BH4, has not hitherto been shown in human malaria. In a recent murine severe malar-
ia model, uncoupling of NOS with increased production of superoxide and impaired microvas-
cular perfusion has been observed, and this was partially reversed by administration of
intravenous BH4 [19]. Our results suggest that uncoupling of NOS due to decreased BH4 bio-
availability and increased BH2, is also a key mechanism of impaired NO bioavailability in
human severe falciparum malaria and in pathogenesis of severe disease.
The physiological role of NOS is oxidation of L-arginine and oxygen reduction to produce
NO and citrulline [14,15,20]. BH4 regulates the coupling of the heme-oxygen intermediate to
oxidation of L-arginine in NOS, and deficiency of BH4 as a co-factor can result in the output
changing from NO to superoxide [14,15,20]. Increased oxidative stress can convert BH4 to the
oxidized form BH2, with the decrease in BH4 increasing superoxide, resulting in a feed forward
cycle with further oxidization of BH4 to BH2 [16]. Since BH2 can serve as a competitive inhibi-
tor at the BH4 binding site in NOS, the BH4/BH2 ratio is likely to determine NOS coupling in
malaria and determine the relative proportions of NO and superoxide production, as others
have observed in vitro [16].
each group on enrollment. Horizontal lines indicate median values for each group. D. Urine Biopterin (μmol/
mmol creatinine) concentrations in each group on enrollment. Horizontal lines indicate median values for
each group. Horizontal bars represent pairwise comparisons between disease groups.
doi:10.1371/journal.ppat.1004667.g001
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Systemic bioavailability of BH4 depends on three pathways of pterin metabolism. First is de
novo synthesis from GTP. A second is regeneration of BH4 from quinonoid dihydrobiopterin
by dihydropteridine reductase (e.g in hepatocytes for phenylalanine hydroxylase activity) and
third is the salvage of 7,8 dihydrobiopterin (BH2) back to BH4 via dihydrofolate reductase (im-
portant for NOS activity in endothelial cells). We found no diminution of total biopterins ex-
creted, suggesting that mechanisms controlling overall biopterin production are not impaired.
Instead the decrease in BH4 associated with severe malaria appeared to result from its oxidation
coupled with inadequate reduction of BH2 to BH4. In vivo recycling of BH2 to BH4 is the main
regulator of the BH4:BH2 ratio, which in turn controls NOS coupling [16].
Our urine collection procedure allowed for capture of pterins, both biopterins and neopter-
ins, in their excreted oxidation states. Our liquid chromatography methods allowed quantifica-
tion of both dihydroneopterin and neopterin, the reduced and oxidized metabolites found in
humans. This was of interest because these measurements provided information, in addition to
biopterins redox status, on the partitioning of oxidized and reduced neopterins. We expected
high total neopterin values in malaria and in septic patients and indeed this was found
(Table 2). Elevated total neopterin has been reported previously and is the result of interferon-
gamma-induced macrophage/monocyte activation with transcriptional induction of GCH1
mRNA [21]. Mononuclear phagocytes have extremely low pyruvoyl tetrahydropterin synthase
(PTPS) activity. Consequently the product of GTPCH catalysis, 7,8 dihydroneopterin triphos-
phate, accumulates, is dephosphorylated intracellularly, and diffuses to extracellular fluid and
then plasma as NH2. Neopterin in healthy controls is excreted primarily as reduced dihydro-
neopterin (NH2:N0 = 4.4). In patients with severe malaria, despite marked elevation in urinary
levels of total neopterins, the portion excreted as NH2 fell significantly (NH2:N0 = 2.0). Impor-
tantly the oxidation of NH2 to N0 is non-enzymatic. This suggests a milieu of oxidative stress
in SM. It provides additional support for the redox imbalance observed for the biopterins, that
is a fall in the ratio of reduced to oxidized metabolites.
An increase in oxidative stress has been observed in Bangladeshi adults with severe falcipa-
rum malaria [22]. This may explain the increased conversion of BH4 to BH2 as seen in this
study, with the decreased BH4/BH2 ratio suggesting impaired recycling of BH2 to BH4 in severe
malaria. Similar to certain cardiovascular diseases [16], our results suggest it is the BH4/BH2
ratio and not BH4 or BH2 alone that reflects NOS coupling in malaria. A decreased BH4/BH2
ratio was associated with an increased risk of severe disease, while decreased BH4 or BH2 alone
were not associated with risk of severe disease. The association of a decreased BH4/BH2 ratio
with impaired microvascular reactivity and endothelial activation, both previously shown to be
associated with increased mortality in malaria, suggests that NOS coupling has an important
role in determining malaria severity.
Our results also show that there is impaired microvascular reactivity and increased endothe-
lial activation in severe sepsis, as we have shown previously [23,24]. However, it is notable that
sepsis patients had high BH4 levels and high BH4/BH2 ratios compared to control subjects and
malaria patients. The findings of increased BH4 levels in sepsis are similar to results from a pre-
vious study in which plasma biopterin levels were measured with high performance liquid
chromatography [25]. The mechanism(s) of impaired vascular function in these sepsis patients
is unclear, but does not appear to be related to impaired BH4 bioavailability. Furthermore, the
high BH4/BH2 ratio in sepsis indicates that the low BH4/BH2 ratio in severe falciparum malaria
is not simply a result of a nonspecific pathogen-wide systemic inflammatory response.
Results from our study also suggest that, in addition to low plasma L-arginine concentra-
tions, increased ADMA and impaired NOS2 expression in severe malaria [5,6,8,10], decreased
BH4 and increased BH2 can also affect NO bioavailability by altering NOS function in malaria.
While increased L-arginine clearance in SM was seen in our pilot study of low dose L-arginine
Decreased Tetrahydrobiopterin and Severity in Adult FalciparumMalaria
PLOS Pathogens | DOI:10.1371/journal.ppat.1004667 March 12, 2015 8 / 13
in severe malaria [12], decreased BH4 and increased BH2 could result in low NO despite the
presence of normal levels of L-arginine. Results of studies with higher doses of L-arginine in se-
vere falciparum malaria (ACTRN 12612000571875) are awaited, but future studies in severe
malaria targeting hypoargininemia may need to consider simultaneously increasing both
L-arginine and BH4 to increase NO production by NOS. Use of intravenous BH4 in patients
with endothelial dysfunction associated with hypercholesterolemia and smoking results in
acute improvement in endothelial NO production [26,27]. However, a randomized controlled
trial of oral BH4 in patients with coronary artery diseases found that BH4 administration only
resulted in increased conversion of BH4 to BH2 with no beneficial effects in clinical outcome
[28]. Using anti-oxidants as adjunctive agents in severe malaria could also increase the BH4/
BH2 ratio, but a recent trial using intravenous N-acetylcysteine (without BH4) in adult severe
malaria did not show a benefit in clinical outcomes [22].
BH4 also plays a role as a co-factor for the enzyme phenylalanine hydroxylase, which converts
phenylalanine to tyrosine [17]. As previously shown [17], both adults and children with clinical
malaria are almost invariably hyperphenylalaninemic at presentation, which originally suggested a
deficiency of BH4 in these patients. Blood levels of phenylalanine are normally tightly regulated be-
tween 30–80 μMby the BH4-dependent phenylalanine hydroxylase (PAH) in the liver [17]. The
skewed BH4/BH2 ratio and high BH2 levels in these subjects correlated significantly with hyperphe-
nylalaninemia. Hyperphenylalaninemia in SM is a transient acute abnormality, and it is relatively
mild compared to the high levels observed chronically in untreated infants with phenylketonuria, a
condition leading to severe brain damage caused by the direct toxicity of phenylalanine [29]. While
it is not clear if the resulting hyperphenylalaninemia in malaria (especially cerebral malaria) is clini-
cally relevant, it provides important supportive evidence for the functional significance of impaired
BH4 bioavailability on BH4-dependent enzyme function in severe malaria.
This study has several limitations. The relatively small number of patients in each group and the
small number of deaths in the SM group do not allow us to examine the independent effect of the
biopterin metabolites on mortality or adjust for confounding variables. The numbers were however
sufficient to demonstrate significant differences between groups. Also, the use of urinary measures of
pterin metabolites as a measure of systemic biopterin bioavailability may not fully reflect intracellular
concentrations in specific organs, though urinary biopterin quantitation has been shown to reflect
systemic biopterin bioavailability [30–33]. It is possible that urinary BH2 and BH4 quantitation may
be affected by renal function, although there was no association between blood creatinine and uri-
nary BH4, BH2, N0 and NH2 in patients with malaria. Furthermore, measurement of the urine BH4/
BH2 ratio is independent of creatinine excretion and is therefore not confounded by renal im-
pairment. Importantly, the specialized collection techniques and assays we have used to measure uri-
nary biopterin metabolite levels allow us to exclude artefactual ex-vivo oxidation.
In summary, the BH4/BH2 ratio is decreased in severe falciparum malaria but not in severe
sepsis, and it is associated with an increased risk of severe disease, impaired microvascular
function and endothelial activation, probably secondary to NOS uncoupling. The elevated lev-
els of BH2 suggest that increased conversion of BH4 to BH2 due to increased oxidative stress
and insufficient recycling of BH2 back to BH4 are the mechanisms of the low BH4/BH2 ratio in
severe malaria. Our findings identify an additional mechanism of impaired NO bioavailability
in severe falciparum malaria and pose an additional challenge to NOS-based adjunctive inter-
ventions to increase NO bioavailability in severe malaria.
Methods
The study was undertaken at the Mitra Masyarakat Hospital, Timika, Papua, Indonesia, an area
with unstable malaria transmission [34]. Patients18 years of age with severe (SM) or
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moderately severe (MSM) Plasmodium falciparummalaria, or severe sepsis (SS) were enrolled as
previously described [18]. SM was defined as peripheral parasitemia with1 modified WHO
criterion of severity [35], andMSMwas falciparummalaria with fever within the past 48 hours,
parasite counts of>1000/μL, requiring admission because of inability to tolerate oral therapy,
but without WHO warning signs or severe criteria as previously described. Healthy controls
(HC) were non-related hospital visitors without fever in the last 48 hours and no parasitemia. As
an additional control for SM, patients with severe sepsis (SS) were also enrolled, defined as clini-
cal evidence of infection, three or more features of the systemic inflammatory response syn-
drome, and evidence of one or more organ dysfunction, with or without septic shock, according
to American College of Chest Physicians criteria, with no parasites by microscopy and a negative
rapid diagnostic test for malaria [18]. All patients were managed by non-study hospital physi-
cians and treated accordingly with antimalarials and antibiotics using hospital protocols.
A standardized history and physical examination were documented. Venous blood was col-
lected on enrolment to measure biomarkers of severity, including lactate and plasma histidine
rich protein 2 (HRP2), a measure of parasite biomass [36,37]. Plasma was obtained within 20
minutes and stored at -70°C for later quantitiation of the NO-dependent measures of endothelial
activation, ICAM-1 and angiopoietin-2 by ELISA, as previously described [37]. Parasite counts
were determined by thick and thin film microscopy. Hemoglobin, biochemistry, acid-base pa-
rameters, and lactate were measured with a bedside analyzer (i-STAT Corp). Reactive hyperemia
peripheral artery tonometry (RH-PAT) was used to measure endothelial NO bioavailability as
previously described [6,18]. RH-PAT uses finger probes to measure digital volume changes mea-
sured by a pressure transducer before and after application of an ischemic stress using a vascular
cuff inflated to 200mmHg for 5 minutes followed by rapid cuff release. The RH-PAT index is a
measure of the volume change and is at least 50% dependent on endothelial NO production.
Near infrared resonance spectroscopy (NIRS) measurements were performed concurrently to
assess microvascular reactivity on enrollment as reported before [18]. In brief, a clinical spectro-
scope (InSpectra 650, Hutchinson Technology) was used noninvasively to assess microvascular
reactivity by measuring differential absorption of oxy (O2Hb) and deoxyhaemoglobin (HHb),
which is then displayed as tissue oxygen saturation (ratio of O2Hb/O2Hb+HHb signals). By in-
ducing an ischemic stress as detailed above, microvascular reactivity is the rate of skeletal muscle
reoxygenation, defined as the rate of increase in StO2 in the first 14 seconds after release of occlu-
sion. According to Beer’s law, this is confined to arterioles, capillaries, and venules of skeletal
muscle with minimal interference from skin blood flow and myoglobin.
Measurement of urine pterin compounds
Measurement of urine pterin concentrations, expressed as biopterins and neopterins in micro-
moles per millimole urine creatinine are used for diagnosis of gene mutations leading to BH4 syn-
thesis, recycling and salvage deficiencies and reflect systemic pterin bioavailability [30–33]. BH4 is
unstable and spontaneously oxidizes to its inactive metabolites, dihydrobiopterin (BH2) and to a
lesser extent fully oxidized biopterin (B0) [38,39]. To prevent ex vivo spontaneous oxidation, urine
was collected, via voluntary micturition or immediately after insertion of a Foley catheter, directly
into vials containing the antioxidant pterin stabilizers 1,4-dithioerythritol (DTE) and diethylene-
triaminepentaacetic acid (DETAPAC) [38,39] (as described in S1). Urine was then frozen at -70°
C, and shipped in liquid nitrogen to Medical Neurogenetics Laboratories, LLC, Atlanta, GAUnit-
ed States. Concentrations of biopterin, 7,8-dihydrobiopterin, 5,6,7,8-tetrahydrobiopterin, and
neopterin were quantified by high performance liquid chromatography using sequential electro-
chemical and fluorescence detection, as previously described [38,39]. Concentrations of pterin
metabolites were normalized to creatinine concentrations in millimoles.
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Statistical methods
Statistical analysis was performed using STATA 11 software. The sample size for the patients
with severe malaria was calculated from our previous study comparing RH-PAT in adults with
severe and uncomplicated malaria with controls [6]. Using the difference and standard devia-
tions found in RH-PAT index between severe malaria and controls, we estimated that a sample
size of 14 in each group would have 80% power to detect a 25% difference between these two
groups. Intergroup differences among malaria (MSM and SM) and controls were compared by
ANOVA or Kruskal-Wallis test, where appropriate, with Wilcoxon Rank-Sum test used for
pairwise comparisons. Pearson’s or Spearman’s correlation coefficients were determined de-
pending on normality of distributions. Partial correlation coefficients were calculated adjusting
for malaria disease severity. Logistic regression was used to determine the association between
binary outcomes and goodness-of-fit was assessed by the Hosmer-Lemeshow test. A two-sided
value of p<0.05 was considered significant.
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